Commonwealth Equity Services’s Esperion Therapeutics ESPR Stock Holding History

Commonwealth Equity Services’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.2K	Sell	13,050 -8,000	-38%	-$22.4K	﹤0.01%	4319
2026 Q1	$57.7K	Sell	21,050 -1,959	-9%	-$6.2K	﹤0.01%	4185
2025 Q4	$85.1K	Buy	23,009 +5,500	+31%	+$17.8K	﹤0.01%	4130
2025 Q3	$46K	Sell	17,509 -5,000	-22%	-$9.67K	﹤0.01%	4169
2025 Q2	$22K	Buy	22,509 +9,772	+77%	+$9.79K	﹤0.01%	4207
2025 Q1	$18K	Sell	12,737 -2,000	-14%	-$3.69K	﹤0.01%	4130
2024 Q4	$32K	Sell	14,737 -4,500	-23%	-$10.5K	﹤0.01%	4015
2024 Q3	$32K	Hold	19,237	–	–	﹤0.01%	3970
2024 Q2	$43K	Buy	19,237 +5,000	+35%	+$11.8K	﹤0.01%	3907
2024 Q1	$38K	Buy	+14,237	New	+$34.6K	﹤0.01%	3920
2015 Q3	–	Sell	-3,575	Closed	-$292K	–	2170
2015 Q2	$292K	Sell	3,575 -40	-1%	-$3.92K	﹤0.01%	1662
2015 Q1	$335K	Buy	+3,615	New	+$233K	﹤0.01%	1566

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Commonwealth Equity Services's ESPR Position: Q2 2026 in Review

Commonwealth Equity Services reduced its Esperion Therapeutics (ESPR) stake by 38% in Q2 2026, selling an estimated $22.4K and leaving 13,050 shares worth $41.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4319.

Commonwealth Equity Services first reported a position in ESPR in Q1 2015 and has held it in 12 quarters since. The position peaked at $335K in Q1 2015. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Commonwealth Equity Services held 13,050 shares of Esperion Therapeutics worth $41.2K as of Q2 2026.
Commonwealth Equity Services sold 8,000 Esperion Therapeutics shares in Q2 2026, an estimated $22.4K.
Esperion Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4319 holding.
Commonwealth Equity Services first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 12 quarters since.
Commonwealth Equity Services's Esperion Therapeutics position peaked at $335K in Q1 2015.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.